GSK's Strategic Path to Sustainable Growth
Cashu Finance·5 min read

TL;DR
- GSK targets £40 billion in sales by 2031.
- New long-acting HIV treatments aim to mitigate patent losses.
- Expansion of discounted medications reflects commitment to accessibility and affordability.
GSK plc (GSK) stands at a crucial juncture as it navigates the complex landscape of biopharmaceuticals, aiming to secure and enhance its market position amidst impending patent expirations and an evolving therapeutic portfolio. The company is bold in its projections, targeting sales of over £40 billion by 2031, an ambitious goal that necessitates innovative strategies, significant R&D investments, and strategic acquisitions to offset potential losses and leverage its current strengths.
Navigating the Patent Cliff
One of the most pressing challenges GSK faces is the imminent expiration of patent protections for its key HIV medicines, notably Tivicay and Triumeq, in the U.S. by April 2028, and Dovato by the end of 2029. These expirations are poised to cause a noticeable decline in their HIV business, as detailed by the President of Business Development David Redfern at the Jefferies Healthcare Conference. With an expected loss in revenue during this critical period, GSK is keenly focused on transitioning towards a pipeline of new treatments and long-acting therapies. This shift is not only necessary to mitigate the expected revenue drop from oral treatments but also highlights GSK's commitment to innovation in HIV treatment through its ViiV business, which is actively developing longer-acting HIV therapies. GSK has ambitious plans to launch a four-month version of Cabenuva, with pivotal data expected in mid-2026, potentially positioning it for market entry by 2028. As noted, both the investigational integrase inhibitor and capsid inhibitor treatments are currently in development, aiming to offer patients more robust options in the coming years. This proactive pipeline expansion reflects GSK's strategy of not just addressing current market needs but anticipating future ones, thereby reinforcing its market presence.

